Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Even as the Serum Institute of India was being praised in the country for being one of the first vaccine-makers to start providing jabs against Covid-19, the company was facing criticism from foreign media. SII's CEO Adar Poonawalla made the revelation during a conversation with Sanjiv Goenka, chairman, RP-Sanjiv Goenka Group at All India Management Association's (AIMA) 7th National Leadership Conclave.
Poonawalla was asked by Goenka how he dealt with overnight stardom as the Covishield vaccine received approval to become one of the first vaccines to be administered in India. The SII CEO said that while Indian media was fair, foreign media criticised him as it didn't suit the West that "an Indian company had the quality and capability of contributing globally in such an important matter".
Poonawalla said that he received praise and criticism in equal measure at the time, and it was a difficult phase for him. The CEO said that he would be happy to "slowly" fade out of the limelight now.

Foreign media attacked Indian vaccine-maker SII for challenging Western firms' dominance, says Adar Poonawalla on Covid pandemic

Foreign media attacked Indian vaccine-maker SII for challenging Western dominance, says Adar Poonawalla

thumbnail
WHY WESTERN MEDIA ATTACKED S.I.I. FOR SUCCESS
&nbsp;
BYTE
SANJIV GOENKA, CONCLAVE CHAIRMAN &amp; CHAIRMAN, RP-SANJIV GOENKA GROUP https://www.youtube.com/watch?v=hlAxKgoP3hQ
(8:20 - 10:04)
 =========================================
CAPTIONS Serum Institute of India CEO's revelation Foreign media criticised SII: Poonawalla Indian firm's rise didn't suit them: SII CEO Happy to be out of limelight now: SII CEO

<div>Serum Institute of India's CEO Adar Poonawalla said that foreign media criticised India and his company amid Covid for challenging Western firms' dominance.</div>

Even as the Serum Institute of India was being praised in the country for being one of the first vaccine-makers to start providing jabs against Covid-19, the company was facing criticism from foreign media.&nbsp;SII's CEO Adar Poonawalla made the revelation during a conversation with Sanjiv Goenka, chairman, RP-Sanjiv Goenka Group at All India Management Association's (AIMA) 7th&nbsp;National Leadership Conclave.
<a href="https://www.editorji.com/partner/all-india-management-association/boosting-india-s-health-security-adar-poonawalla-in-conversation-with-sanjiv-goenka-1649847929961" target="_blank">Adar&nbsp;Poonawalla</a> was asked by Goenka how he dealt with overnight stardom as the Covishield vaccine received approval to become one of the first vaccines to be administered in India. The SII CEO said that while Indian media was fair, foreign media criticised him as it didn't suit the West that "an Indian company had the quality and capability of contributing globally in such an important matter".
ALSO WATCH:&nbsp;<a href="https://www.editorji.com/partner/all-india-management-association/boosting-india-s-health-security-adar-poonawalla-in-conversation-with-sanjiv-goenka-1649847929961" target="_blank">AIMA 2022: Serum Institute&rsquo;s Adar Poonawalla on building capacity and resilience</a>
Adar Poonawalla said that he received praise and criticism in equal measure at the time, and it was a difficult phase for him. The CEO said that he would be happy to "slowly" fade out of the limelight now.
Also Watch:&nbsp;<a href="https://www.editorji.com/partner/all-india-management-association/aima-conclave-2022-cea-v-anantha-nageswaran-talks-about-building-for-a-better-economy-1649924594182" target="_blank">AIMA 2022: CEA V Anantha Nageswaran talks about building for a better economy</a>

India today starts booster shots for all above the age of 18. Earlier the booster was only given to all individuals above the age of 60. 
The booster or precaution dose is the third dose of the vaccine, double vaccinated people can get. 
All individuals above the age of 18 can now get the dose provided nine months have passed since the second dose. The precaution dose, however, will be the same as the previous two vaccine the individual has received. 
Only private players will be administering the dose for now.
Your COWIN account lets you how how many days left till you're eligible for the precaution dose. 
Unlike those above 60 whose booster doses are free, those in the 18-59 age bracket will need to pay. Both Covishield and Covaxin are now priced at Rupees 225. In addition to that cost, hospitals are allowed to charge up to Rs 150 in service charge over and above the cost of the vaccine.
Both vaccines had a higher price tag. Covaxin was priced at Rupees 1200 and Covishield at Rs 600. Both companies slashed the prices drastically after discussions with the government. 

Covid precaution dose for 18+: all you need to know

Booster shots are available to all above 18 starting today. Here's all you need to know. 

India today starts Covid booster shots for all above the age of 18. Earlier the booster was only given to all 60 and above&nbsp;individuals.&nbsp;
The booster&nbsp;or precaution dose is the third dose of the vaccine that double vaccinated people can get.&nbsp;
All those above the age of 18 can now get the dose provided nine months have passed since the second dose. The precaution dose, however, will be the same as the previous two vaccine doses the individual received.&nbsp;
Only private players will be administering the dose for now.
Your COWIN&nbsp;account lets you how how many days left till you're eligible for the precaution dose.&nbsp;
Unlike those above 60 whose booster doses are free, those in the 18-59 age bracket will need to pay. Both Covishield and Covaxin are priced at Rupees 225. In addition to that cost, hospitals are allowed to charge up to Rs 150 in service charge.
Both vaccines had a higher price tag. Covaxin&nbsp;was priced at Rupees 1200 and Covishield&nbsp;at Rs 600. Both companies slashed the prices drastically after discussions&nbsp;with the government.&nbsp;

Booster shots are available to all above 18 starting today. Here's all you need to know.&nbsp;

India has rolled out&nbsp;Covid-19 booster shots for all above the age of 18. Earlier the booster was only given to all 60 and above&nbsp;individuals.&nbsp;
The booster&nbsp;or precaution dose is the third dose of the vaccine that double vaccinated people can get.&nbsp;
All those above the age of 18 can now get the dose provided nine months have passed since the second dose. The precaution dose, however, will be the same as the previous two vaccine doses the individual received.&nbsp;
Only private players will be administering the dose for now.
Your COWIN&nbsp;account lets you hknow how many days left till you're eligible for the precaution dose.&nbsp;
Unlike those above 60 whose booster doses are free, those in the 18-59 age bracket will need to pay. Both Covishield and Covaxin are priced at Rs 225. In addition to that cost, hospitals are allowed to charge up to Rs 150 in service charge.
Both vaccines had a higher price tag. Covaxin&nbsp;was priced at Rs 1200 and Covishield&nbsp;at Rs 600. Both companies slashed the prices drastically after discussions&nbsp;with the government.&nbsp;
ALSO WATCH:&nbsp;<a href="https://www.editorji.com/coronavirus/covid-19-booster-dose-covishield-covaxin-prices-slashed-to-225-1649508949133">Covid-19 booster dose: Covishield, Covaxin prices slashed to ₹225</a>

India's apex body on immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, news agency PTI reported on Sunday.
Presently, the second dose of Covishield is given between 12-16 weeks after the first dose under the National COVID-19 Vaccination Strategy.
The National Technical Advisory Group on Immunisation (NTAGI) has not yet suggested any change in the schedule of Bharat Biotech's Covaxin, whose second dose is administered 28 days after the first dose.   The recommendation for Covishield is yet to be implemented in the national COVID-19 vaccination programme.
"The latest recommendation of NTAGI is based on recent global scientific evidence derived from programmatic data," PTI quoted an official source as saying. 
"According to it, when the second dose of Covishield is given eight weeks onwards, the antibody response generated is almost similar when administered at an interval of 12 to 16 weeks," the PTI report said. 
The decision will lead to accelerated administration of the second dose of Covishield to the remaining six to seven crore individuals amid rising cases in several countries, the source said.
The government had on May 13, 2021 extended the gap between the first and second doses of the Covishield vaccine from 6-8 weeks to 12-16 weeks based on the recommendations by NTAGI.
NTAGI provides guidance and advice to the Union Health Ministry on immunisation services for the effective control of vaccine-preventable diseases in the country.

2nd Covishield dose can be given between 8-16 weeks after first dose: top vaccine body

India's apex body on immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, according to reports

India's apex body on immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, news agency PTI reported on Sunday.
Presently, the second dose of Covishield is given between 12-16 weeks after the first dose under the National COVID-19 Vaccination Strategy.
News agency PTI&nbsp;quoted a source as saying that when the second dose of Covishield is given eight weeks onwards, the antibody&nbsp;response generated is almost similar when administered&nbsp;at an interval of 12 to 16 weeks.&nbsp;
The decision will lead to accelerated administration of the second dose of Covishield to the remaining six to seven crore individuals amid rising cases in several countries, the source said.
The government had on May&nbsp;13, 2021 extended the gap between the first and second&nbsp;doses&nbsp;of&nbsp;the Covishield&nbsp;vaccine&nbsp;from 6-8 weeks to 12-16 weeks based on the recommendations by NTAGI.

India's apex body on immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, according to reports

India's apex body on immunisation has recommended administering the second dose of Covid-19 vaccine Covishield between eight and 16 weeks after the first dose, news agency PTI reported on Sunday.
Presently, the second dose of Covishield is given between 12-16 weeks after the first dose under the National COVID-19 Vaccination Strategy.
The National Technical Advisory Group on Immunisation (NTAGI) has not yet suggested any change in the schedule of Bharat Biotech's Covaxin, whose second dose is administered 28 days after the first dose. &nbsp; The recommendation for Covishield is yet to be implemented in the national COVID-19 vaccination programme.
"The latest recommendation of NTAGI is based on recent global scientific evidence derived from programmatic data," PTI&nbsp;quoted an official source as saying.&nbsp;
"According to it, when the second dose of Covishield is given eight weeks onwards, the antibody&nbsp;response generated is almost similar when administered&nbsp;at an interval of 12 to 16 weeks," the PTI report said.&nbsp;
The decision will lead to accelerated administration of the second dose of Covishield to the remaining six to seven crore individuals amid rising cases in several countries, the source said.
The government had on May&nbsp;13, 2021 extended the gap between the first and second&nbsp;doses&nbsp;of&nbsp;the Covishield&nbsp;vaccine&nbsp;from 6-8 weeks to 12-16 weeks based on the recommendations by NTAGI.
NTAGI provides guidance and advice to the Union Health Ministry on immunisation services for the effective control of vaccine-preventable diseases in the country.

India's drug regulator has granted regular market approval for Covid-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said on Thursday.
The two vaccines so far had restricted emergency use authorisation. 
"The regulator has upgraded the permission for Covaxin and Covishield from restricted use in emergency situations to normal new drug permission in the adult population with certain conditions," Mandaviya said.
According to news agency PTI, Covaxin and Covishield will soon be available at hospitals and clinics for people to buy. 
Gradually, the vaccine will be available in the market at a price lower than at what it was being sold earlier at private hospitals, the report added. 
The health minister also clarified that govt's free vaccination drive will continue even after the vaccines are made available in the regular market. 

Covishield, Covaxin granted regular market approval: what it means

India's drug regulator has granted regular market approval for Covid-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said on Thursday.

India's drug regulator has granted regular market approval for Covid-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said on Thursday.
The two vaccines so far had restricted emergency use authorisation.&nbsp;
According to news agency PTI, Covaxin&nbsp;and Covishield&nbsp;will soon be available at hospitals and clinics for people to buy against prescription.&nbsp;
However, the vaccine will not be available for purchase at local chemists with or without prescriptions for now
&nbsp;
The health minister also clarified that govt's&nbsp;free vaccination drive will continue even after the vaccines are made available in the regular market.&nbsp;

According to news agency PTI, Covaxin&nbsp;and Covishield&nbsp;will soon be available at hospitals and clinics for people to buy.&nbsp;

India's drug regulator has granted regular market approval for Covid-19 vaccines Covishield and Covaxin for use in the adult population subject to certain conditions, Health Minister Mansukh Mandaviya said on Thursday.
The two vaccines so far had restricted emergency use authorisation.&nbsp;
"The regulator has upgraded the permission for Covaxin&nbsp;and Covishield from restricted use in emergency situations to normal new drug permission in the adult population with certain conditions," Mandaviya said.
According to news agency PTI, Covaxin&nbsp;and Covishield&nbsp;will soon be available at hospitals and clinics for people to buy against prescription.&nbsp;
However, the vaccine will not be available for purchase at local chemists with or without prescriptions for now.&nbsp;
Also watch:&nbsp;<a href="https://www.editorji.com/coronavirus/covid-vaccine-precaution-doses-can-be-taken-only-3-months-after-recovery-govt-1642827608095">Covid vaccine, precaution doses can be taken only 3 months after recovery: Govt</a>
The health minister also clarified that govt's&nbsp;free vaccination drive will continue even after the vaccines are made available in the regular market.&nbsp;

The subject expert committee (SEC) of India's central drug authority has recommended granting regular market approval to Covid vaccines Covishield and Covaxin. The vaccines currently have emergency use authorisation only. Central Drugs Standard Control Organisation (CDSCO)  took to Twitter to confirm that its "SEC has recommended for upgrade of Covishield and Covaxin status from restricted use in emergency situations to grant of new drug permission with conditions in the adult population, DCGI will evaluate the recommendations and give its decision.What is the difference? An EUA is granted based on review of data by the medical authorities to merely seek it's effectiveness in combating a disease. Only after review of a larger set of data based on a wider set of parameters such as safety, effectiveness and also involves site/facility visits by the medical authorities. So what changes, Why do drug makers want full approval?Under regular (or full) market approval the vaccine would be available even at chemists associated with hospitals and not just centres approved by the government right now. Also a full market approval gives security for production and supply as an EUA can be withdrawn at any point for a particular drug. But withdrawal/recall of an 'approved' drug is not common. Also insurance typically doesn’t pay for products under an EUA so that also weighs on the medication. Do any global vaccines have full approval or are they also on EUAs?On August 23, 2021, the US FDA gave the first full regulatory approval for a Covid vaccine to Pfizer-BioNTech’s Comirnaty for individuals 16 years and older

EJ Explains: What is regular market approval vs emergency use approval for vaccines

Can you soon buy your vaccine from your local hospital's chemist? The expert panel is recommending to  the government that vaccines get upgraded from emergency use to full approval.

EJ Explains: EUA vs full market approval, what's the difference 

An expert panel of India's central drug authority recommended regular market approval to Covid vaccines Covishield and Covaxin.&nbsp;

The subject expert committee (SEC)&nbsp;of India's central drug authority has recommended granting regular market approval to Covid vaccines Covishield and Covaxin. The vaccines currently have emergency use authorisation only.&nbsp; Central Drugs Standard Control Organisation (CDSCO)&nbsp; took to Twitter to confirm that its "SEC has recommended for upgrade of Covishield and Covaxin status from restricted use in emergency situations to grant of new drug permission with conditions in the adult population, DCGI will evaluate the recommendations and give its decision. What is the&nbsp;difference?&nbsp; An EUA&nbsp;is granted based on review of data by the medical authorities to merely seek it's effectiveness in combating a disease.&nbsp; Only after review of a larger set of data based on a wider set of parameters such as safety, effectiveness and also involves site/facility visits by the medical authorities.&nbsp; So what changes, Why do drug makers want full approval? Under&nbsp;regular (or full) market approval the vaccine would be available even at chemists associated with hospitals and not just centres approved by the government right now.&nbsp; Which means that if you wanted a booster shot you would be able to get the vaccine from a hospital chemist and have your doctor administer it for you. Also a full market approval gives security for production and supply as an EUA&nbsp;can be withdrawn at any point for a particular drug. But withdrawal/recall of an 'approved' drug is not common.&nbsp; Also insurance typically doesn&rsquo;t pay for products under an EUA&nbsp;so that also weighs on the medication.&nbsp; Do any global vaccines have full approval or are they also on EUAs? On August 23, 2021, the US FDA gave the first full regulatory approval for a Covid vaccine to Pfizer-BioNTech&rsquo;s Comirnaty for individuals 16 years and older

It's been more than a year since the first case of novel coronavirus was detected. Little did anyone know that the contagion would bring the world to a standstill, cause a shutdown of economic activities globally and lead to so many deaths.
So far, more than 1.30 crore people have received a coronavirus vaccine in India. India&rsquo;s vaccines are absolutely safe and while there have been no cases reported of any adverse effects, some recipients have claimed to experience certain&nbsp;side effects or mild illness. This however should not stop us from getting the vaccination, as it is the only way forward out of this.&nbsp;
For the most part, getting a Covid-19 vaccination shouldn&rsquo;t change any of your typical health, fitness or wellness routines, or at least not for more than a day or two.&nbsp;&nbsp;
Here are some of the things you need to keep in mind&nbsp;after getting vaccinated.
A recipient of the vaccine is monitored at the vaccine centre itself to guard against any immediate severe allergic reactions. People are allowed to leave only after it has been ascertained that that is not the case.
Side effects like pain at the injection site and fever are common. This is no reason to panic. Some other side effects like chills and fatigue might also be expected, but these go away in a few days. It typically takes a few weeks after vaccination for the body to build protection (immunity) against the virus.
A person could still get infected by Covid-19 in the few days immediately following the vaccination because the person would not have had enough time to develop immunity. Therefore, basic precautionary measures must be followed- face masks, hand hygiene and physical distancing in public places are an absolute non negotiable.&nbsp;
Lastly, the vaccination protects an individual against the virus, but no vaccine has 100 percent efficacy. If you still show symptoms of COVID-19, get yourself tested.
&nbsp;
&nbsp;
&nbsp;
&nbsp;

Explained: Dos and don'ts after COVID-19 vaccine dose

Dos - Make sure you are monitored at the vaccine centre itself to guard against any immediate severe allergic reaction.
Don'ts- One should not panic with side effects like swelling, fever, chills and fatigue, these go away in a few days.
 Dos -It takes a few weeks for the body to build protection against the virus, so basic precautionary measures must be followed.
Dos- If you still have symptoms of COVID-19, get yourself tested.

It's been more than a year since the first case of novel coronavirus was detected. Little did anyone know that the contagion would bring the world to a standstill, cause a shutdown of economic activities globally and lead to so many deaths.
So far, more than 1.30 crore people have received a coronavirus vaccine in India. India&rsquo;s vaccines are absolutely safe and while there have been no cases reported of any adverse effects, some recipients have claimed to experience certain&nbsp;side effects or mild illness. This however should not stop us from getting the vaccination, as it is the only way forward out of this.&nbsp;
For the most part, getting a Covid-19 vaccination shouldn&rsquo;t change any of your typical health, fitness or wellness routines, or at least not for more than a day or two.&nbsp;&nbsp;
Here are some of the things you need to keep in mind&nbsp;after getting vaccinated.
A recipient of the vaccine is monitored at the vaccine centre itself to guard against any immediate severe allergic reactions. People are allowed to leave only after it has been ascertained that that is not the case.
Side effects like pain at the injection site and fever are common. This is no reason to panic. Some other side effects like chills and fatigue might also be expected, but these go away in a few days. It typically takes a few weeks after vaccination for the body to build protection (immunity) against the virus.
A person could still get infected by Covid-19 in the few days immediately following the vaccination because the person would not have had enough time to develop immunity. Therefore, basic precautionary measures must be followed- face masks, hand hygiene and physical distancing in public places are an absolute non negotiable.&nbsp;
Lastly, the vaccination protects an individual against the virus, but no vaccine has 100 percent efficacy. If you still show symptoms of COVID-19, get yourself tested.

covishield

Categories